Sionna Therapeutics initiated with a Strong Buy at Raymond James

Raymond James initiated coverage of Sionna Therapeutics (SION) with a Strong Buy rating and $45 price target. Sionna has the best chance in the industry at breaking Vertex’s (VRTX) strong technological monopoly in cystic fibrosis, argues the analyst, who sees Sionna as “well positioned” with key proof of concept data coming with SION-719 in combination with Trikafta and SION-451 in two proprietary combos, both in mid-2026. The firm thinks the NBD1 mechanism is “differentiated enough and potent enough to move the efficacy bar in this disease,” the analyst added.